Form 483

Continental Manufacturing Chemist, Inc. Form 483, 2019-07-30

FDA issued a Form 483 to Continental Manufacturing Chemist, Inc. on 2019-07-30 with 10 public-safe observations.

483· Form 483 issuedHuman Drugs10 observations

Continental Manufacturing Chemist, Inc. · Madrid, United States · Issued July 30, 2019

Overview

  • 10 public-safe observations are available for this inspection.
  • 5 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

30 Jul 2019
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Eric T Huebler, Doan T Nguyen, Doan N Singh

30 Jul 2019
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Eric T Huebler, Doan T Nguyen, Doan N Singh

30 Jul 2019
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Eric T Huebler, Doan T Nguyen, Doan N Singh

30 Jul 2019
21 CFR 211.68(a)

Calibration/Inspection/Checking not done

Cited by Eric T Huebler, Doan T Nguyen, Doan N Singh

30 Jul 2019
21 CFR 211.84(e)

Rejecting When Specifications Not Met

Cited by Eric T Huebler, Doan T Nguyen, Doan N Singh

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.142(b)Cited across public-safe Form 483 observations2x
21 CFR 211.22(d)Cited across public-safe Form 483 observations2x
21 CFR 211.67(b)Cited across public-safe Form 483 observations2x
21 CFR 211.68(a)Cited across public-safe Form 483 observations2x
21 CFR 211.84(e)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 10 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere